Isentress

Type: Product

Name: Isentress

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Merck & Co., Inc. Management Presents at UBS Global Healthcare Conference (Transcript)

Merck & Co., Inc. (MRK) UBS Global Healthcare Conference Call May 20, 2013 10:30 AM ETMarc Goodman - UBSSo good morning everybody, thanks for joining us for the conference. I am Marc Goodman, I cover large cap pharma and specialty pharma for UBS. And ... [Published Seeking Alpha - May 20 2013]

Entities: Merck & Co Inc, Patent, Mergers & Acquisitions, SITAGLIPTIN

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Isentress

Global dolutegravir market: Latest market research analysed

- GlobalData has released its new PharmaPoint Drug Evaluation report, "". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed ... [Published TransWorldNews - May 08 2013]

Entities: Dolutegravir, HIV/AIDS, Antiretroviral Drugs, Isentress, Patient

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Elvitegravir

Global elvitegravir market: New market research published

Entities: Elvitegravir, HIV/AIDS, Isentress, Gilead Sciences Inc

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Merck & Co Inc

Merck Releases 1Q 2013 Financial Results

Merck, known as MSD outside the United States and Canada, announced financial results for the first quarter of 2013. In a release on May 1, the Company noted that non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first ... [Published Individual.com - May 06 2013]

Entities: Merck & Co Inc, Forex, investigational

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Merck net sales fall by 9% to $10.7 bn in Q1, net profit by 8.3%

Merck & Co has suffered a major setback during the first quarter ended March 2013 on account of loss of exclusivity and adverse foreign exchange rates. Its sales declined by nine per cent to $10,671 million from $11,731 million in the corresponding period ... [Published PharmaBiz - May 02 2013]

Entities: Merck & Co Inc, Net Profit, Declination, Forex

First reported May 02 2013 - Updated May 02 2013 - 2 reports

infliximab

Merck cuts outlook as Q1 sales fall

But new R&D chief highlights potential of company's near-term pipeline Merck & Co joined its peer Pfizer in cutting its financial guidance for 2013 after reporting lower-than-expected first quarter revenues.Sales fell 9 per cent to $10.7bn in the quarter, ... [Published PMLive - May 02 2013]

Entities: Merck & Co Inc, Roger Perlmutter, infliximab, Research & Development, SIMPONI

First reported May 01 2013 - Updated May 01 2013 - 1 reports

DuPont - E I du Pont de Nemours & Co

6 Dow Stocks That Pay Double the Yield of the T-Bond: Part II

Meena is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.In Part I of this series, we discussed three of the six Dow stocks that currently pay yields at least twice as high ... [Published Motley Fool - May 01 2013]

Entities: DuPont - E I du Pont de Nemours & Co, Merck & Co Inc, Titanium Dioxide, Motley Fool

First reported May 01 2013 - Updated May 01 2013 - 4 reports

Merck Cuts Outlook Amid Slumping Singulair Sales, Boosts Buyback

WHITEHOUSE STATION (dpa-AFX) - Healthcare giant Merck & Co., Inc. (MRK) reported Wednesday a profit for the first quarter that declined eight percent from last year, reflecting lower sales amid generic competition for blockbuster asthma drug Singulai ... [Published FinanzNachrichten.de - May 01 2013]

Entities: Singulair, Merck & Co Inc, Drugs, Cozaar

First reported Apr 29 2013 - Updated Apr 30 2013 - 2 reports

FDA rejects two Gilead HIV drugs as standalone products

By Toni ClarkeWASHINGTON (Reuters) - Gilead Sciences Inc said on Monday that U.S. health rejected two of its HIV drugs as standalone therapies, citing deficiencies in documentation and validation of certain quality testing procedures.Gilead said it is ... [Published Reuters India - Apr 29 2013]

Entities: Gilead Sciences Inc, Elvitegravir, HIV/AIDS, Drugs

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

Elvitegravir (HIV) - Forecast and Market Analysis to 2022

(M2 PRESSWIRE via COMTEX News Network) -- Research and Markets has announced the addition of the " " report to their offering. GlobalData has released its new PharmaPoint Drug Evaluation report, Elvitegravir (HIV) - Forecast and Market Analysis to 2022. ... [Published PredictWallStreet - Apr 23 2013]

Entities: Elvitegravir, HIV/AIDS, market analysis, Isentress, Gilead Sciences Inc

First reported Apr 11 2013 - Updated Apr 12 2013 - 2 reports

ISENTRESS (Raltegravir) Tablet, Film Coated [REMEDYREPACK INC. ]

Updated Date: Apr 12, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Apr 12 2013]

Entities: Isentress, raltegravir

First reported Mar 22 2013 - Updated Mar 22 2013 - 1 reports

Human medicines European Public Assessment Report (EPAR): Isentress, raltegravir, Revision: 18, Authorised

[Published Pending EC decisions and European Public Assess ... - Mar 22 2013]

Entities: Isentress, raltegravir

Quotes

...patent expiries coupled with the impact of currency and other headwinds," said Kenneth C Frazier, chairman and chief executive officer, Merck. "During the quarter, we took focused actions to reach our EPS target while at the same time advancing Merck's pipeline in our laboratories and through strategic deals and partnerships. I remain confident in the future opportunities for our strong and diverse business and committed to delivering long-term value to our shareholders."

Merck Releases 1Q 2013 Financial Results [Published Individual.com - May 06 2013]

"I am doing a very detailed review of programmes, of process and people and already two weeks in, I can say there is some opportunities for acceleration and for productivity enhancement" he said. Meantime, however, Merck's R&D spend looks set to increase in 2013 over 2012

Merck cuts outlook as Q1 sales fall [Published PMLive - May 02 2013]

...Analysts are concerned, however, and Andrew Baum at Citibank issued a research note saying that "the weakness of Merck's quarter can only be regarded as a clarion call for management and investors"

Merck & Co sales slide, $15 billion share buyback unveiled [Published Pharma Times - May 02 2013]

..."The market is very competitive," Schechter added. "We are seeing rebate and pricing pressures as newer competitors seek to increase their market share" by offering health plans bigger discounts and rebates

Generic competition cuts Merck's Q1 sales, profit [Published WHAS 11 - May 01 2013]

More Content

sort by: Date \| Relevance
Merck & Co., Inc. Management Presents at UBS Gl... [Published Seeking Alpha - May 20 2013]
Global dolutegravir market: Latest market resea... [Published TransWorldNews - May 08 2013]
Global elvitegravir market: New market research... [Published TransWorldNews - May 08 2013]
Merck Releases 1Q 2013 Financial Results [Published Individual.com - May 06 2013]
Merck net sales fall by 9% to $10.7 bn in Q1, n... [Published PharmaBiz - May 02 2013]
Merck cuts outlook as Q1 sales fall [Published PMLive - May 02 2013]
Merck & Co sales slide, $15 billion share buyba... [Published Pharma Times - May 02 2013]
Generic competition cuts Merck's Q1 sales, profit [Published WHAS 11 - May 01 2013]
Patent Application Titled "Deuterated Hiv Attac... [Published Equities.com - May 01 2013]
6 Dow Stocks That Pay Double the Yield of the T... [Published Motley Fool - May 01 2013]
Merck Cuts Outlook Amid Slumping Singulair Sale... [Published FinanzNachrichten.de - May 01 2013]
Merck Earnings Decline Y/Y, Cuts Outlook - Anal... [Published Quote.com India - May 01 2013]
Merck Cuts Outlook Amid Slumping Singulair Sale... [Published RTTNews.com - May 01 2013]
Merck Earnings Decline Y/Y, Cuts Outlook - Anal... [Published Quote.com United States - May 01 2013]
FDA rejects two Gilead HIV drugs as standalone ... [Published Reuters India - Apr 29 2013]
UPDATE 1-FDA rejects two Gilead HIV drugs as st... [Published Reuters - Apr 29 2013]
Elvitegravir (HIV) - Forecast and Market Analys... [Published PredictWallStreet - Apr 23 2013]
A Reporter's Journey: Living With HIV [Published Edge Miami - Apr 22 2013]
New Market Study Published: Dolutegravir (HIV) ... [Published Live-PR.com - Apr 21 2013]
A reporter's journey: Living with HIV [Published Bay Area Reporter - Apr 18 2013]
Dolutegravir (HIV) - Forecast and Market Analys... [Published Individual.com - Apr 15 2013]
ISENTRESS (Raltegravir) Tablet, Film Coated [RE... [Published DailyMed Drug Label Updates for the last seven ... - Apr 12 2013]
ISENTRESS (Raltegravir) Tablet, Film Coated [RE... [Published DailyMed Drug Label Updates for the last seven ... - Apr 11 2013]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Mar 22 2013]
Research and Markets: Isentress (HIV) - Forecas... [Published Business Wire Health News - Mar 20 2013]
Merck Announces Appointment of Roger M. Perlmut... [Published Yahoo! Finance - Mar 07 2013]
Merck & Co net earnings up marginally at $1,729... [Published PharmaBiz - Oct 29 2012]